Rasagiline Tablets

The Defense Logistics Agency Troop Support Medical is seeking pharmaceutical suppliers to provide Rasagiline tablets under a national contract that will serve multiple federal agencies including the Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. This five-year pharmaceutical procurement covers two specific line items: Rasagiline 0.5 mg tablets in 30-count bottles and Rasagiline 1 mg tablets in 30-count bottles, both requiring FDA approval and current Good Manufacturing Practices compliance. The solicitation mandates that distribution must occur through Pharmaceutical Prime Vendors, and contractors will be subject to a 0.5% cost recovery fee on all sales. The procurement follows a Lowest Price Technically Acceptable evaluation methodology, prioritizing cost efficiency while ensuring technical compliance with all specified requirements. Interested offerors must submit their proposals electronically through the Defense Logistics Agency Internet Bid Board System by October 6, 2025, at 3:00 PM EST, along with comprehensive documentation including trade agreements information, representations and certifications, and past performance data.

This opportunity operates under the NAICS code 325412 for Pharmaceutical Preparation Manufacturing and carries no set-aside designation, making it available to businesses of all sizes. The contract structure includes a base year plus four option years, with estimated annual quantities of 5,828 bottles for the 0.5 mg tablets and 35,099 bottles for the 1 mg tablets. Large business offerors must provide subcontracting plans as part of their submission requirements, while all participants must demonstrate their ability to meet the technical specifications and distribution requirements. The solicitation does not identify current incumbents or specific budget ranges, though the substantial annual quantities suggest a significant contract value over the potential five-year performance period. Performance will occur through the established Pharmaceutical Prime Vendor network, ensuring broad distribution capability across the participating federal agencies and their respective healthcare systems.